Oxford Nanopore Technologies continues to drive innovation in genomics and epigenetics. Recent Parliamentary discussions have highlighted the company’s role in advancing scientific research and supporting the life sciences sector.
A ministerial statement from late last year reaffirmed the government’s commitment to cutting-edge research in genomics and epigenetics, recognising Oxford Nanopore’s pioneering sequencing technology.
A Parliamentary debate towards the end of 2024 explored epigenetics’ potential to transform healthcare through improved diagnostics, early disease detection, and tailored treatments. Oxford Nanopore was commended for its technology’s ability to decode the epigenome with remarkable precision. During the debate, Baroness Merron highlighted the importance of government support for genomics and epigenetics research, emphasising Oxford Nanopore’s role in driving forward these advancements. Read the full statement here.
This expansion of the epigenetics programme is an early example of collaboration between Oxford Nanopore and HMG, building on the plans to form a strategic partnership announced on 5 November.
